Antidepressant Labeling Should Reflect Negative Pediatric Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
With study results for several drugs failing to show pediatric efficacy, an FDA advisory committee suggests revising a standard labeling statement that efficacy "has not been established" in children. The committee also recommends that labeling highlight the need for suicide monitoring.
You may also be interested in...
SSRIs And Suicide To Be Discussed By Pediatric Advisory Cmte. In September
Joint session with Psychopharmacologic Advisory Committee will be new cross-center committee's first meeting.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: